Blood Cell Factors Market

The global blood cell factors market size is anticipated to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the prevailing blood-related disorders and rising reports of cancer related to blood.  

Blood cell factors are made up of proteins that produce the key components of blood cells including white blood cells. The deficiency of these blood cell can cause several blood-related diseases and those patients having this type of disease are normally required to increase the blood level in their body.  The blood is produced by the body with the help of a key organ, kidney as it releases hormone called as erythropoietin (EPO), which is responsible for blood production in the body. One key disease caused due to the deficiency of blood in the body is termed as anemia.

Get Free Sample Report

Several factors responsible for the deficiency of blood cell factors in a body are low level of hemoglobin, abnormal white blood cells (WBC), and lack of vitamins or minerals. The problem starts when the DNA of the normal WBC gets damaged due to disease infection and the cell growth gets malfunctioned. As a result of this condition, the WBC begins to multiply its development at a rapid pace. Unlike the process of normal blood cells that die and are replaced by the new cells, these damaged cells do not die and are continuously growing. This leads to the development of a high number of defective blood cells in the body and there is less space available for the normal blood cells, which causes blood deficiency in the body.

This process makes the patient sick and produces symptoms such as fatigue, dizziness, vertigo, drop in blood pressure, and sometimes can lead to coma or death. According to the report of the World Health Organization (WHO), around 42% of children of five years of age or less and nearly 40% of pregnant women worldwide are expected to suffer from anemia in the near future. The report also estimated that half a billion of women population of reproductive age are likely to face anemic worldwide. The high prevalence of blood deficiency cases indicate that the blood cell factors market is set to propel in the near future.

Market Trends, Drivers, Restraints, and Opportunities

• Rising geriatric population who are exposed to more risk to develop anemia globally is projected to drive the market growth during the projected period.
• Development of advanced technology for diagnostic kits and adoption of innovative methods for screening techniques are expected to boost the market growth in the coming years.
• Increasing funding by governmental as well as non-governmental organizations and several government initiatives to establish advanced laboratory facilities for cell factors are pushing to fuel the market revenue.
• Growing numbers of blood-related diseases such as leukemia, cancer, and renal dysfunctions are key drivers to upsurge the market expansion during the projected period.
• Lack of awareness about the cell factors development especially in developing and underdeveloped countries are proving to be major restraints to the market.

Scope of Blood Cell Factors Market Report

The report on the global blood cell factors market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Blood Cell Factors Market Segment Insights

Filgrastim segment is expected to grow at a rapid pace

Based on drug types, the global blood cell factors market is divided into lenograstim, filgrastim, and pegfilgrastim. The filgrastim segment is expected to grow at a rapid pace in the coming years due to its wide applications for blood cell deficiency treatment. Filgratism is a form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes. The colony stimulating factors are growth factors, which are produced by the body for the growth of blood cells to increase blood counts. Some types of colony stimulating factors stimulate the bone marrow to produce blood cells. Filgratism is a drug, which is sold under brand names such as Grastofil, Accofil, Zarxio, Granix, Nivestim, Nivestym, Neupogen, and Ratiograstim. These drugs are also used in cancer therapy.

Meanwhile, the pegfilgrastim segment is projected to account for a key market share during the forecast period owing to its rising adoption for the blood cells treatment. The drug is a long acting type of PEGylated form of the recombinant human granulocyte colony-stimulating factor used to stimulate the production of neutrophils in the blood. These has different brand names including Neulasta, Fulphila, Udenyca, and Ziextenzo.

Get Free Sample Report

Colony stimulating factors segment is anticipated to register a high CAGR

On the basis of treatments, the market is bifurcated into colony-stimulating factors and epoetin alfa. The colony stimulating factors (CSF) segment is anticipated to register a high CAGR during the projected period. The colony-stimulating factors stimulate the production of blood cells and encourage their ability to function. The CSFs are not directly used in cancer treatment but they promote blood cells to enhance person’s immune system.  The two types of CSFs are granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF).

The GM-CSF segment is anticipated to hold a key market share in the coming years due to extensive use of the method as a major biological therapy as it increases the number of some types of WBC (neutrophils and monocytes). They are also working on finding the GM-CSF as a vaccine for some types of cancers.

The epoetin alfa segment is anticipated to grow substantially in the coming years due to its commercial success in the market. Epoetin alfa, also known as erythropoietin, is a hormone produced by the kidney as well as by the liver though in small quantity due to low oxygen levels in the body. The amplified number of blood cells especially red blood cells resolve symptoms of weakness as it provides adequate level of oxygen to all parts of body.

Get Free Sample Report

North America is anticipated to dominate the global market

In terms of regions, the global blood cell factors market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market in the coming years owing to extensive funding on research and development activities, advanced infrastructure of the healthcare sector, and availability of skilled professional in the region. However, the market of Asia Pacific is projected to exhibit a healthy growth rate during the forecast period due to the developing advanced techniques, high population for treatment, and increasing people awareness of the blood cell deficiency treatment in the region. Meanwhile, the market of Latin America is expected to register a moderate growth rate in the coming years while the market of Middle East & Africa is estimated to exhibit a sluggish rate in the years to come.

Get Free Sample Report

Segments

The global blood cells factors market has been segmented on the basis of

Drug Types

• Lenograstim
• Filgrastim
• Pegfilgrastim

Treatments

• Colony-stimulating Factors
• Epoetin Alfa

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Beckman Coulter
• Erma Inc.
• Abbott Lab.
• Nihon Kohden
• Boule Diagnostics
• Biochem
• Horiba Abx
• EdanRayto
• Orphee

Competitive Landscape

Key players competing in the global blood cell factors market are Beckman Coulter; Erma Inc.; Abbott Lab.; Nihon Kohden; Boule Diagnostics; Biochem; Horiba Abx; EdanRayto; and Orphee.